Amy Krambeck, MD, highlights 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting.
In this video, Amy Krambeck, MD, discusses 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting. Krambeck is a professor of Urology, Department of Urology, Northwestern University, Feinberg School of Medicine.
The following 6 abstracts are previewed:
1. LBA01-02 (Morsy, et al):Efficacy of Low-Power Thulium Laser Enucleation of Prostate Larger Than 80 Grams
2. LBA01-05 (Beltran, et al):Surgical Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement By Holmium Laser Enucleation of the Prostate Versus Transurethral Resection of the Prostate And Open Adenomectomy
3. LBA01-06 (Amparore, el):Long Term Follow-Up of an International Multicenter Prospective Study in Application of Temporary Implantable Nitinol Device (iTind) in Men With Lower Urinary Tract Symptoms for BPH
4. LBA02-04 (Yang, et al): Effect of Extracorporeal Shock Wave Lithotripsy Combined With Extracorporeal Physical Vibration Lithotripsy in the Treatment of Patients With Ureteral Calculi
5. LBA02-08 (Harper, et al): Risk Factors for Increased Stent-Associated Symptoms Following Ureteroscopy for Urinary Stones: Results From the Urinary Stone Disease Research Network (USDRN) Stents Study
6. LBA02-10 (Mookerji, et al): Assessing the Risks of A Positive Urine Culture in Uncomplicated Renal Colic Patients
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.